Market Cap 5.79B
Revenue (ttm) 1.48B
Net Income (ttm) 241.66M
EPS (ttm) N/A
PE Ratio 23.68
Forward PE 42.74
Profit Margin 16.37%
Debt to Equity Ratio 0.00
Volume 2,485,500
Avg Vol 2,419,152
Day's Range N/A - N/A
Shares Out 166.25M
Stochastic %K 82%
Beta 0.44
Analysts Strong Sell
Price Target $43.70

Company Profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders....

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 353 1 772 8000
Address:
Connaught House, 1 Burlington Road Dublin 4, Dublin, Ireland
StockSqueeze_
StockSqueeze_ Apr. 1 at 9:03 PM
Live Account Update Down 0.7%today. I learned that high volatility stocks like $ALKS can trick my system. I paid the price today but that's how we learn and build better. Back again tomorrow.
0 · Reply
HoHoHoHum
HoHoHoHum Apr. 1 at 2:04 PM
$ALKS IMO perhaps next leg to 40ish after some consolidation.
0 · Reply
fallondpicks
fallondpicks Mar. 31 at 9:22 PM
11 #stockbreakouts $AGIO (200-day MA and Base), $ALKS (gap), $UNIT (gap). One $1-2.
0 · Reply
Few_erish
Few_erish Mar. 31 at 7:45 PM
$ALKS more strength than chatter
0 · Reply
mikesterz7
mikesterz7 Mar. 31 at 6:56 PM
$ALKS Alkermes, like Centessa, is also developing an orexin 2 receptor for narcolepsy called alixorexton.
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 31 at 6:55 PM
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes $ALKS $LLY $CNTA https://stocktwits.com/news/equity/markets/alks-stock-surges-on-lilly-centessa-buyout-igniting-sleep-pipeline-hopes/cZE55YcRIVr
0 · Reply
simzy
simzy Mar. 31 at 4:42 PM
$ALKS this is done
1 · Reply
ryguy69
ryguy69 Mar. 31 at 3:25 PM
$ALKS sympathy bounce. Short
0 · Reply
Otus
Otus Mar. 31 at 3:25 PM
$ALKS nice to see some activity here. This is a solid long term play. Surprised there’s not more interest on this board. I own around 6500 shares. Not a huge position but big enough that I’m very confident in the future.
1 · Reply
ClassifiedTrades
ClassifiedTrades Mar. 31 at 1:44 PM
$UGRO hitting targets $ALKS $APLS
0 · Reply
Latest News on ALKS
Top 2 Health Care Stocks That May Implode In April

Apr 1, 2026, 8:34 AM EDT - 4 days ago

Top 2 Health Care Stocks That May Implode In April

ASRT


Alkermes to Present at the Stifel 2026 Virtual CNS Forum

Mar 10, 2026, 4:00 PM EDT - 25 days ago

Alkermes to Present at the Stifel 2026 Virtual CNS Forum


Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 12:47 PM EST - 5 weeks ago

Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript


Alkermes plc Announces CEO Succession Plan

Feb 25, 2026, 6:55 AM EST - 5 weeks ago

Alkermes plc Announces CEO Succession Plan


Alkermes: Avadel Deal And Vibrance-2 Unlock Upside

Jan 8, 2026, 9:16 PM EST - 3 months ago

Alkermes: Avadel Deal And Vibrance-2 Unlock Upside


Alkermes to Participate in Two Upcoming Investor Conferences

Nov 25, 2025, 4:00 PM EST - 4 months ago

Alkermes to Participate in Two Upcoming Investor Conferences


Alkermes raises offer for Avadel after Lundbeck bid

Nov 19, 2025, 6:08 AM EST - 4 months ago

Alkermes raises offer for Avadel after Lundbeck bid

AVDL


Alkermes plc (ALKS) Shareholder/Analyst Call Transcript

Nov 17, 2025, 5:37 PM EST - 4 months ago

Alkermes plc (ALKS) Shareholder/Analyst Call Transcript


Alkermes Response to Avadel Announcement

Nov 14, 2025, 7:45 AM EST - 5 months ago

Alkermes Response to Avadel Announcement


Avadel Receives Unsolicited Proposal from Lundbeck

Nov 14, 2025, 5:45 AM EST - 5 months ago

Avadel Receives Unsolicited Proposal from Lundbeck

AVDL


Alkermes' narcolepsy drug meets main goal in a mid-stage trial

Nov 12, 2025, 7:35 AM EST - 5 months ago

Alkermes' narcolepsy drug meets main goal in a mid-stage trial


FORM 8.1(a) & (b) (Opening Position Disclosure)

Nov 5, 2025, 9:00 AM EST - 5 months ago

FORM 8.1(a) & (b) (Opening Position Disclosure)


Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 3:21 PM EDT - 5 months ago

Alkermes plc (ALKS) Q3 2025 Earnings Call Transcript


Alkermes plc Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 7:00 AM EDT - 5 months ago

Alkermes plc Reports Third Quarter 2025 Financial Results


Alkermes plc (ALKS) M&A Call Transcript

Oct 22, 2025, 10:53 AM EDT - 5 months ago

Alkermes plc (ALKS) M&A Call Transcript


Alkermes to acquire Avadel for up to $2.1 billion

Oct 22, 2025, 7:11 AM EDT - 5 months ago

Alkermes to acquire Avadel for up to $2.1 billion

AVDL


Alkermes Appoints Joshua Reed as Chief Financial Officer

Sep 12, 2025, 9:00 AM EDT - 7 months ago

Alkermes Appoints Joshua Reed as Chief Financial Officer


Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)

Sep 8, 2025, 2:34 PM EDT - 7 months ago

Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)


Alkermes: A More Than Solid Quarter

Jul 30, 2025, 5:08 PM EDT - 8 months ago

Alkermes: A More Than Solid Quarter


Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 2:47 PM EDT - 8 months ago

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript


Alkermes plc Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 7:00 AM EDT - 8 months ago

Alkermes plc Reports Second Quarter 2025 Financial Results


StockSqueeze_
StockSqueeze_ Apr. 1 at 9:03 PM
Live Account Update Down 0.7%today. I learned that high volatility stocks like $ALKS can trick my system. I paid the price today but that's how we learn and build better. Back again tomorrow.
0 · Reply
HoHoHoHum
HoHoHoHum Apr. 1 at 2:04 PM
$ALKS IMO perhaps next leg to 40ish after some consolidation.
0 · Reply
fallondpicks
fallondpicks Mar. 31 at 9:22 PM
11 #stockbreakouts $AGIO (200-day MA and Base), $ALKS (gap), $UNIT (gap). One $1-2.
0 · Reply
Few_erish
Few_erish Mar. 31 at 7:45 PM
$ALKS more strength than chatter
0 · Reply
mikesterz7
mikesterz7 Mar. 31 at 6:56 PM
$ALKS Alkermes, like Centessa, is also developing an orexin 2 receptor for narcolepsy called alixorexton.
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 31 at 6:55 PM
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes $ALKS $LLY $CNTA https://stocktwits.com/news/equity/markets/alks-stock-surges-on-lilly-centessa-buyout-igniting-sleep-pipeline-hopes/cZE55YcRIVr
0 · Reply
simzy
simzy Mar. 31 at 4:42 PM
$ALKS this is done
1 · Reply
ryguy69
ryguy69 Mar. 31 at 3:25 PM
$ALKS sympathy bounce. Short
0 · Reply
Otus
Otus Mar. 31 at 3:25 PM
$ALKS nice to see some activity here. This is a solid long term play. Surprised there’s not more interest on this board. I own around 6500 shares. Not a huge position but big enough that I’m very confident in the future.
1 · Reply
ClassifiedTrades
ClassifiedTrades Mar. 31 at 1:44 PM
$UGRO hitting targets $ALKS $APLS
0 · Reply
Nomorelies
Nomorelies Mar. 31 at 12:58 PM
$ALKS $BIIB buyout of $APLS at more than double the price.
0 · Reply
HoHoHoHum
HoHoHoHum Mar. 31 at 12:52 PM
$ALKS LLY b.o of CNTA for $6.5B giving us a boost.
0 · Reply
Nomorelies
Nomorelies Mar. 31 at 12:08 PM
$ALKS Nice!!
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 1:23 AM
$ALKS Share Price: $29.92 Contract Selected: Nov 20, 2026 $36.0 Calls Buy Zone: $1.91 – $2.36 Target Zone: $3.12 – $3.82 Potential Upside: 54% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 11:44 PM
$ALKS Current Stock Price: $27.74 Contracts to trade: $28.0 ALKS Mar 20 2026 Call Entry: $5.10 Exit: $9.33 ROI: 83% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Otus
Otus Mar. 9 at 3:48 PM
$ALKS overreacting to leadership change.
0 · Reply
erevnon
erevnon Feb. 26 at 5:47 PM
Wells Fargo maintains Alkermes $ALKS at Overweight and raises the price target from $37 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 4:44 PM
$ALKS beats Q4 — yet the stock drops 7%. What’s the market seeing? 📉 Earnings and revenue both topped estimates, but shares slid after the company announced a CEO transition plan. Strong numbers, leadership change — that combo can create uncertainty. Is this dip a reactionary selloff or a sign of deeper concerns? Full breakdown of the quarter and transition plan 👉 https://www.zacks.com/stock/news/2876085/alkermes-down-despite-q4-earnings-beat-announces-leadership-change?cid=sm-stocktwits-2-2876085-teaser-35317&ADID=SYND_STOCKTWITS_TWEET_2_2876085_TEASER_35317
0 · Reply
ZacksResearch
ZacksResearch Feb. 26 at 3:44 PM
$ALKS down 7% despite Q4 earnings beat — what's weighing on the stock? 🤔 📉 Total revenues fell 10.6% from the year-ago quarter, with a sharp 43.4% drop in manufacturing and royalty revenues. 📈 However, sales of proprietary products increased 2.5%, driven by strong demand for Lybalvi. Understand the market reaction here 👉 https://www.zacks.com/stock/news/2876085/alkermes-down-despite-q4-earnings-beat-announces-leadership-change?cid=sm-stocktwits-2-2876085-body-35309&ADID=SYND_STOCKTWITS_TWEET_2_2876085_BODY_35309
0 · Reply
d_risk
d_risk Feb. 25 at 7:11 PM
$ALKS - Alkermes plc - 10K - Updated Risk Factors ALKS adds major new risks from the Avadel deal and LUMRYZ: integration and synergy shortfalls, REMS and DEA/controlled-substance compliance, third‑party manufacturing and quota limits, plus heavy new debt and heightened exposure to U.S. drug pricing and Medicaid/Medicare policy shifts that could hit revenues. #Pharmaceuticals #MergersIntegration #RegulatoryCompliance #DebtRisk #U.S.DrugPricing 🟢 Added 🟠 Removed https://d-risk.ai/ALKS/10-K/2026-02-25
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 12:17 PM
$ALKS Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.30 down -66.67% YoY • Reported revenue of $384.55M down -10.57% YoY • Alkermes plc expects 2026 total revenues between $1.73B and $1.84B, with GAAP Net Loss projected from $115M to $135M, and Adjusted EBITDA between $370M and $410M.
0 · Reply
Estimize
Estimize Feb. 25 at 11:00 AM
$ALKS reported - EPS and - revenue for Q4. http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_content=ALKS&utm_medium=
0 · Reply